Quote:
Originally Posted by zanpar321
Is Radotinib ABL to beat Nilotinib? | The Science of Parkinson's
June 17, 2018 - The competition to stop/reverse Parkinson's is intense!
Our efforts to slow/halt the progression of Parkinson’s are attempting to attack the condition on many different fronts, and (as in the case of the cAbl-inhibitors and GLP-1 agonists – see previous post) we now have multiple weapons potentially available on some of those battle lines.
Ironically in another recent post I commented about the crazy pace of the research at the moment (Click here for that post), and this post is a perfect example of that manic speed. Just days after publishing fascinating results dealing with a novel GLP-1 agonist in models of Parkinson’s, that same research group – led by Prof Han Seok Ko of Johns Hopkins University Medical school – published the research report that was reviewed in this post dealing with a completely different type of drug that exhibits interesting properties in models of Parkinson’s.
A lot of excitement is associated with the efforts to re-purpose the cancer drug Nilotinib for Parkinson’s, and today’s post reinforces the idea that other pharmaceutical companies are also focusing on shifting similar ABL inhibitor drugs to neurodegenerative conditions.
It will be interesting to see how quickly Ilyang Pharmaceutical initiates clinical testing of Radotinib for Parkinson’s.
|
Yes, there are better versions of both c-abl inhibitors and glp-1 agonists in development. There are three ongoing trials for approved glp-1 agonists with several newer ones still in clinical research for approval. We willing be reviewing funding applications next week at the LinkedIn Clinical Trials annual meeting for a newly approved c-abl inhibitor and glp-1 agonist to possibly begin neurological research.